Servier Reports Strong Performance and Growth Prospects for 2030

Servier Reports Strong Performance in 2024/25

On January 27, 2026, Servier, an independent international pharmaceutical organization, announced remarkable financial results for the 2024/25 fiscal year, achieving group revenues of €6.9 billion. This figure marks a notable 16.2% increase from the previous year, primarily attributed to surging sales in oncology, especially in the United States.

During this financial year, the company benefitted significantly from various partnership agreements, especially in the fields of oncology and neurology. These collaborations have substantially enhanced their research and development (R&D) portfolio, particularly targeting rare diseases.

Olivier Laureau, the President of Servier, expressed confidence in these results, stating that they reflect the effectiveness of their innovative strategies aimed at patient care and the unwavering commitment from their employees. He emphasized that these achievements are pivotal in progressing toward the company’s ambitious goals set for 2030.

Financial Highlights
In the fiscal year of 2024/25, Servier's revenue hit €6.9 billion, surpassing the €6 billion goal. This growth was driven by a 16.9% increase in sales volume, equating to an additional €1 billion compared to last year, despite facing an adverse currency effect. The strong demand for their medicines and effective cost management resulted in a significant boost in EBITDA margins, reaching 28.2%, up from 22.2% in 2023/24.

The oncology sector, in particular, demonstrated robust growth, representing 32.2% of total revenue. This area saw revenues reaching €2.21 billion, a remarkable increase of 54.6%, largely due to the successful launch of Voranigo® within the U.S. market, benefiting many patients with rare forms of brain cancer.

Advancements in Oncology and Neurology
The past financial year was notable for several clinical advancements in oncology, as well as the establishment of partnerships aimed at developing new treatments for patients with rare cancers. Servier's focus on oncology is expected to continue as they aim to become a leading provider in both oncology and neurology. The company’s strategic partnerships, including collaborations with Black Diamond Therapeutics and BioNova Pharmaceuticals, aim to enhance their pipeline and improve outcomes for patients diagnosed with difficult-to-treat cancers.

In neurology, Servier intends to carve out a significant niche, directing efforts towards rare diseases associated with genetic and immuno-inflammatory mechanisms. The company is currently focusing on three major areas: refractory epilepsy, rare movement disorders, and neuromuscular diseases. They have begun Phase 1 clinical trials targeting a specific type of rare epilepsy in children, showcasing commitment to addressing pressing medical needs through innovative solutions.

Pharmaceutical Innovations and Patient Care Initiatives
Servier’s ongoing innovation strategy aims to enhance the productivity of R&D initiatives, crucial for addressing the needs of patients suffering from rare conditions. The integration of artificial intelligence (AI) throughout the drug development process is paving the way for faster and more efficient treatment discoveries. Their approach not only advances their oncology efforts but also supports developments in cardiometabolic therapies, solidifying their leading position in hypertension care.

The inclusion of Single Pill Combinations (SPCs) aimed at simplifying treatment regimens for patients with chronic diseases reflects Servier’s commitment to improving adherence to therapy, which is crucial for delivering optimal healthcare outcomes.

Conclusion and Future Outlook
Servier's robust financial performance and strategic focus on oncology and neurology have set the stage for anticipated revenues of €10 billion by 2030, paired with a targeted EBITDA margin of at least 30%. With ongoing commitment to therapeutic advancements, patient-centered care, and impactful partnerships, Servier is well-positioned to continue playing a vital role in enhancing global health outcomes. Their future-focused agenda, supporting innovative drug developments and collaborations, underscores their mission to improve the quality of life for patients around the world.